Skip to main content
Clinical Trials/NCT05798312
NCT05798312
Completed
N/A

Randomized and Multicenter Study to Evaluate the Impact of a Customizable Support Material in the Knowledge and Satisfaction of Breast Cancer Patients

Medicos e Investigadores en la Lucha contra el Cancer de Mama1 site in 1 country125 target enrollmentMay 21, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Medicos e Investigadores en la Lucha contra el Cancer de Mama
Enrollment
125
Locations
1
Primary Endpoint
Knowledge
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The goal of this clinical trial is to evaluate if a customizable support material allows to improve the knowledge about the stage and subtype of the disease, as well as the indicated treatments, in comparison with a non-customizable support material among patients with breast cancer.

The main question it aims to answer is:

• What is the impact of delivering a customizable support material so that patients with breast cancer know and remember the stage and subtype of their disease, as well as the indicated treatments, compared to non-customizable support material?

Participants in the intervention group will be provided customizable support material while those in the standard group will receive a non-customizable material.

Detailed Description

In the present investigation, it is planned to carry out a prospective, multicenter study, randomized and blinded to the statistician. Patients with a recent diagnosis of CM and who are scheduled to have their first consultation in which their options will be discussed of treatment to participate in the study. To those who agree to participate and sign the informed consent, the protocol coordinator of each center will randomly assign them to the intervention group or the standard group (in a 1:1 ratio) before the appointment medical. The intervention group will receive customizable support material while the Standard group will receive a non-customizable material (Annex 2). Additionally, you will be instructed to the intervention group that the support material received can be filled with the information discussed with the medical team. The protocol coordinator will obtain sociodemographic data and clinicopathology of the medical records of the participants. After the next visit follow-up, the coordinator will apply to both groups questionnaires about the knowledge of the patient about his own disease, satisfaction with the support material received and perceived ability to participate in discussions about their treatment, and the comprehension of written materials (CHLT-6). After one month, both groups will respond knowledge questionnaires to assess long-term information retention, disease uncertainty (SF-MUIS) and satisfaction with medical information provided (EORTC-QLQ-INFO25).

Registry
clinicaltrials.gov
Start Date
May 21, 2021
End Date
March 13, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Medicos e Investigadores en la Lucha contra el Cancer de Mama
Responsible Party
Principal Investigator
Principal Investigator

Cynthia Villarreal Garza

MD, DSc

Medicos e Investigadores en la Lucha contra el Cancer de Mama

Eligibility Criteria

Inclusion Criteria

  • Women with a recent diagnosis of primary breast cancer treated at the participant centers
  • Women who will receive information about their options for the first time treatment
  • Provision of informed consent to participate in the study

Exclusion Criteria

  • Patients who have already started systemic treatment for breast cancer
  • Patients with medical records not available for data collection

Outcomes

Primary Outcomes

Knowledge

Time Frame: 1-month

Evaluate if a customizable support material allows to improve the knowledge about the stage and subtype of the disease, as well as the indicated treatments, in comparison with a non-customizable support material as measured by the knowledge questionnaire assessing patients' knowledge of their disease extension (in situ vs invasive cancer); clinical stage; estrogen, progesterone and HER2 receptor status; and treatments to which they are candidates.

Secondary Outcomes

  • Patient satisfaction(1-month)
  • Comprehension(1-month)
  • Satisfaction with medical information(1-month)
  • Illness uncertainty(1-month)

Study Sites (1)

Loading locations...

Similar Trials